Lite Strategy, Inc. annual report, FY2020

Filing identity and reporting period

Important mismatch: The supplied filing is MEI Pharma, Inc.’s Form 10-K for the fiscal year ended June 30, 2021—not a Lite Strategy, Inc. filing or a 2019 Q4 report. The summary below reflects the supplied filing.

Business context

MEI Pharma is a clinical-stage oncology company with four drug candidates: zandelisib, voruciclib, ME-344 and pracinostat. It had no commercialized products; reported revenue primarily came from collaboration and license arrangements.

Financial results and liquidity

FY2021 revenue declined 12% from FY2020, principally because FY2020 included recognition of the transfer of the KKC ex-U.S. license. Research and development expense more than doubled to $69.4 million, including $46.1 million for zandelisib; general and administrative expense rose to $24.4 million.

FY2021 GAAP net loss included a non-cash $18.1 million gain from revaluing warrant liabilities. Excluding that gain, the company cited a net loss of approximately $68.7 million, versus approximately $23.1 million in FY2020 excluding a non-cash warrant revaluation expense. The warrant liability was $22.4 million at year-end.

At June 30, 2021, cash and cash equivalents were $8.5 million and short-term U.S. government investments were $144.9 million, totaling $153.4 million. Total assets were $174.1 million, total liabilities $132.7 million, and stockholders’ equity $41.4 million. No borrowings are identified in the supplied financial statements; lease liabilities totaled $8.3 million. Management said available resources were expected to fund operations for at least 12 months from the report’s issuance. The company expects operating losses and negative operating cash flow to continue.

Material changes, outlook and risks

• FY2021 operating loss widened as clinical development spending increased. Operating cash flow was a $32.0 million use, compared with cash provided in FY2020, which included a $79.6 million KKC license payment.
• The company reported $25.1 million of FY2021 KKC-related revenue. The KKC agreement provides for shared U.S. development costs and profits, with KKC responsible for ex-U.S. development and commercialization costs, subject to exceptions. Potential milestones and ex-U.S. royalties are contingent, not assured revenue.
• Topline results from the Phase 2 TIDAL zandelisib study were expected in calendar Q4 2021. The Phase 3 COASTAL study was ongoing; COVID-19 had negatively affected TIDAL enrollment and could continue to disrupt trials, manufacturing and regulatory timelines.
• Management reported encouraging early zandelisib response data, but these results are from small clinical cohorts and do not establish approval or commercial success. FDA marketing approval had not been obtained for the candidates.
• Helsinn discontinued the pracinostat Phase 3 AML study in July 2020 after an interim futility analysis; FDA withdrew the candidate’s breakthrough therapy designation. The pracinostat MDS study was complete, with analyses underway, and no additional studies were planned.
• Key risks include clinical-trial efficacy and safety uncertainty, regulatory delays, reliance on collaborators and contract manufacturers, further funding needs, potential equity dilution, competition, and COVID-19-related disruption. The company had a $60 million ATM facility available and other shelf-registration capacity.
• Pracinostat-related securities class and derivative actions were voluntarily dismissed without prejudice in February 2021. The filing does not report an active case from those matters.

Key facts for investors to verify

• Confirm the filing and issuer identity: the supplied document is MEI Pharma’s FY2021 10-K, inconsistent with the requested company and period.
• Check actual TIDAL results and subsequent regulatory developments against the filing’s Q4 2021 expectation, and track COASTAL enrollment and timing.
• Assess the cash runway using subsequent cash burn, trial spending, and financing activity; the 12-month runway statement is management’s estimate as of September 2021.
• Review the terms, milestones, cost-sharing, and revenue-recognition assumptions in the KKC agreement, including the unrecognized deferred revenue and contingent payments.
• Monitor potential dilution from outstanding warrants, options, and ATM or shelf offerings, and distinguish non-cash warrant revaluation effects from operating performance.